NON-PAINFUL DISEASES
only speculate that a mixing vat broke, dumping its precious load
onto the floor—but it was salvaged. Or that the mixing vat wasn't
cleaned thoroughly from it's last use.
Persons with illness due to taking tryptophane developed an
extremely high eosinophil count in their blood test—an index of
parasitism, too. Parasitism, that would have led to insomnia in
the first place! Were these unfortunate victims seeing the cause or
the result of their tryptophane use? This tragic event should have
led to a discovery of the heavy pollution, a revelation of the
industrial manufacturing process, and a safeguarding against any
repetition. It has not been done (certainly not publicly).
Foreign countries' manufacturing processes do not come un-
der U.S. scrutiny or jurisdiction, although some imported prod-
ucts must pass tests. There are no safeguards against repetition of
the tryptophane experience. It behooves us to demand safe
supplements and medicines. It is not the list of ingredients that
informs. Lot analysis, after bottling, would give us the necessary
safeguard. The presence of filth contamination and toxins cannot
be completely avoided but the consumer can make informed
choices if he or she knows it is there. Disclosure, of course, is
the bane of the manufacturing business. Interest rate disclosure
was the bane of the money lending business. Such important
matters can't be left to “self-regulation” policies. The consumers
must simply demand to know what they are consuming.
Ruby Adair, 14, ached all over, had ringing in her ears, sinus problems
and chronic fatigue. She couldn't get to sleep, ever; and had been
half a year out of school already. She had intestinal flukes in her
stomach. In three weeks she had eliminated them with parasite
herbs and she could go to sleep naturally.